IXABEPILONE - Generic Drug Details

What are the generic sources for ixabepilone and what is the scope of patent protection?

Ixabepilone is the generic ingredient in one branded drug marketed by R-pharm Us Llc and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for ixabepilone. One supplier is listed for this compound.

Summary for IXABEPILONE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	56
Clinical Trials:	114
What excipients (inactive ingredients) are in IXABEPILONE?	IXABEPILONE excipients list
DailyMed Link:	IXABEPILONE at DailyMed

Recent Clinical Trials for IXABEPILONE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Allarity Therapeutics	Phase 2
Yale University	Phase 2
R-Pharm-US, LLC	Phase 2

See all IXABEPILONE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for IXABEPILONE

L01DC	Other cytotoxic antibiotics
L01D	CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for IXABEPILONE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
IXEMPRA KIT	Injection	ixabepilone	15 mg/vial and 45 mg/vial, single- use vials	022065	1	2012-04-16

US Patents and Regulatory Information for IXABEPILONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-002	Oct 16, 2007		RX	Yes	Yes
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-001	Oct 16, 2007		RX	Yes	Yes

Expired US Patents for IXABEPILONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-002	Oct 16, 2007
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-002	Oct 16, 2007
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-001	Oct 16, 2007
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-001	Oct 16, 2007
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-002	Oct 16, 2007
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-002	Oct 16, 2007

IXABEPILONE Market Analysis and Financial Projection

Last updated: February 14, 2026

Market Overview of Ixabepilone

Ixabepilone is a chemotherapeutic agent developed primarily for the treatment of metastatic or locally advanced breast cancer, especially in cases resistant to anthracyclines or taxanes. It is an epothilone B analog targeting microtubules, approved by the U.S. FDA in 2007 but later marked by limited market penetration and eventual market withdrawal in certain regions, notably the U.S. in 2018.

Market Dynamics

Market Size and Demand

• The global breast cancer drug market was valued at approximately $9.4 billion in 2022, with targeted therapies representing a significant segment.
• Ixabepilone's initial peak sales reached around $74 million in the U.S. in 2012 but declined sharply post-2013 due to safety concerns, limited efficacy data, and competition from biosimilars and newer agents.
• The drug's use was mostly confined to second-line or later therapies in metastatic settings; demand decreased as newer agents like immune checkpoint inhibitors gained prominence.

Competitive Landscape

• Ixabepilone faced competition from other microtubule inhibitors such as taxanes and vinca alkaloids.
• It lost market share against newer chemotherapies and targeted agents with better safety profiles.
• Associated with adverse events, including neutropenia and peripheral neuropathy, further limited its adoption.

Regulatory and Market Access Factors

• The drug was approved with indications for metastatic breast cancer resistant to anthracyclines, taxanes, and capecitabine.
• Its discontinuation in the U.S. was announced in 2018 after the manufacturer, Bristol-Myers Squibb, decided to cease its distribution due to declining sales, which was driven by limited reimbursement and market preferences.

Financial Trajectory

Year	Estimated Global Sales (USD millions)	Notes
2009	~20	Launch year; initial sales rapid rise
2012	74	Peak sales in the U.S.
2013-2015	Steady decline	Competition intensifies, side effect issues arise
2016-2018	Below 10	Market contraction, limited use post-approval withdrawal decision

• The decline parallels the expiration of patent protections and the entry of biosimilars and competitive therapies.
• The revenue drop was compounded by safety issues and evolving treatment guidelines favoring newer agents.

Current Market Position

• Market presence is minimal; the drug remains available in certain regions under compassionate use or research settings.
• Clinical development halted for new indications or formulations.
• No recent regulatory approvals or significant R&D activity reported, signaling a commercial phase-out.

R&D and Future Outlook

• No active pipeline development or new indications to extend the commercial life.
• The focus for existing formulations is on managing legacy uses in specific patient subsets.
• Investment in Ixabepilone-focused R&D is unlikely, with strategic shifts toward novel agents and immunotherapies in breast cancer.

Key Factors Influencing Future Prospects

• The erosion of market share due to safety concerns.
• The evolution of breast cancer treatments toward targeted therapies and immunotherapies.
• Potential niche use in research or rare indications, though no indications are currently under investigation.

Summary

The market for ixabepilone exhibits characteristics of a declining pharmaceutical asset. Initial high sales in the early 2010s have, due to safety profile issues, market competition, and evolving standards of care, resulted in a significant contraction. The drug's withdrawal from the U.S. market and negligible global sales figures reflect a shift toward newer, better-tolerated therapies for metastatic breast cancer.

---

Key Takeaways

• Ixabepilone's peak sales occurred in 2012 (~$74 million), with rapid decline afterward.
• Market share reduced by safety issues, competition, and regulatory decisions.
• No active R&D or new indications indicate a dead-end asset with minimal future revenue potential.
• The drug illustrates challenges facing late-stage chemotherapies in evolving oncology landscapes.
• Investors and pharma developers should consider the implications of safety profiles, market competition, and treatment paradigm shifts in oncology drug markets.

---

FAQs

1. Why was ixabepilone withdrawn from the U.S. market?
Bristol-Myers Squibb decided to cease distribution in 2018 due to declining sales, limited reimbursement, and competition from other therapies.

2. Are there ongoing clinical trials involving ixabepilone?
No prominent or registered trials currently aim to develop new indications or formulations for ixabepilone.

3. What were the main safety concerns associated with ixabepilone?
Neutropenia and peripheral neuropathy were common adverse events, contributing to limited patient tolerability.

4. How does ixabepilone compare to other microtubule inhibitors?
It was similar in mechanism to taxanes but was associated with higher toxicity and limited efficacy in resistant cases.

5. What is the outlook for similar chemotherapeutic agents?
Agents with better safety profiles, targeted mechanisms, and integration into personalized medicine show more promise than traditional chemotherapies like ixabepilone.

---

References

[1] FDA Drug Approval Package. (2007). Ixabepilone.
[2] EvaluatePharma. (2022). Global Breast Cancer Market Report.
[3] Bristol-Myers Squibb. (2018). Market withdrawal announcement.